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Human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs) can theoretically be con-
verted into any somatic cell type. hESCs and hiPSCs carrying genetic defects can now be produced tomodel
diseases in vitro. We suggest several guiding principles to help ensure an optimal fit between technology and
disease.Considerable hope surrounds the use of
disease-specific pluripotent stem cells
as the starting materials for generating
surrogate models of human disease. The
concept is simple: Pluripotent stem cells
are capable, by definition, of differenti-
ating into most if not all adult cell types.
It should be possible, the argument goes,
to follow disease progression in a dish
and by doing so gain valuable insight
into the pathophysiology of that disease,
discover new prognostic biomarkers, and
ensure a continuous supply of afflicted
cell types for drug screening and dis-
covery. It is still too early to know whether
this hope is well founded. Nevertheless,
prudence dictates that we carefully con-
sider the potential fit between the type
of disease and existing knowledge re-
garding the feasibility of emulating that
disease through in vitro differentiation of
pluripotent stem cells. Any scientist plan-
ning to subject their selected disease to
this type of approach should bear in
mind several key considerations.
Routes to Disease-Specific
Pluripotent Stem Cells and Progeny
Until three years ago, human disease-
specific pluripotent cells could be made
only by genetic modification of existing
human embryonic stem cells (hESCs) or
by the generation of new hESCs from em-
bryos carrying those monogenic diseases
detectable via preimplantation genetic
diagnosis (PGD) (Figure 1). For different
reasons each of these methods is very
restrictive, and few diseases have been
captured in this way. In addition, many
genetic diseases display variable pene-
trance and severity of clinical symptoms
from patient to patient. This lack of
consistency is due to the complex inter-
actions of genetic background and envi-244 Cell Stem Cell 5, September 4, 2009 ª2ronment and may extend to the properties
of derived pluripotent stem cells. Knowl-
edge of the clinical history of the donor
could inform experimental design and
interpretation. However, disease-specific
hESCs can have no such clinical history
owing to their origins. The advent of in-
duced pluripotent stem cells (iPSCs) has
transformed the prospects for disease
modeling (Takahashi and Yamanaka,
2006; Park et al., 2008; Rubin, 2008):
iPSCs can be made with cells taken
from babies or adults of all ages with full
medical records and suffering from virtu-
ally any genetic disease, whether simple
or complex. With more than 5000 known
genetic diseases, it would appear that a
bonanza of specific information might be
gained from using iPSCs to study them.
Experimentally, we envisage that the
schematic shown in Figure 1 will be adop-
ted in some form. Cells can be taken from
a living patient or a frozen tissue bank.
Tissue banks generally supply very little
clinical information on the specific donor
but offer the advantage of convenience.
iPSCs can be generated by any of a variety
of methods although those that leave no
genetic footprint (nonintegrating vectors,
excisable genetic elements, or methods
that use small chemicals and/or proteins)
seem preferable (Yu et al., 2009; Kim
et al., 2009; Feng et al., 2009).
Differentiation of the chosen pluripotent
cell type into the target cell type(s) of
choice can then be performed if suitable
protocols are available. If possible, such
cells should be compared with similar
cells taken from a patient (ideally the
somatic cell donor), even if the main target
of a particular study is a much earlier
appearing progenitor. This ‘‘reality’’ check
is useful because it can validate the fidelity
of in vitro differentiation. However, irre-009 Elsevier Inc.spective of its inclusion, any insight gath-
ered from these studies should lead to
predictions that can be further tested in
animal or other cell models, if either is
available. Alternatively, or in parallel, the
manufactured cells can be used for drug
testing or screening.
Points to Consider in the Choice
of Disease
What is the feasibility of making an infor-
mative pluripotent stem cell model for
your chosen disease? To assist in the
decision-making process, we present an
annotated check list (Table 1) that offers
some guidance. Although many of the
notes are self explanatory, some addi-
tional comments are made here.
For many diseases, only iPSC genera-
tion could provide the desired pluripotent
stem cell type. Where a choice of hiPSC
or hESC models is possible, it should be
noted that although mouse iPSCs can
yield newborn offspring from tetraploid
complementation (Zhao et al., 2009; Kang
et al., 2009), there are differences be-
tween iPSCs and ESCs (Chin et al.,
2009). For monogenic diseases, one
benefit of the targeted manipulation of a
hESC line is the availability, in principle,
of a perfect control (the unmodified line)
to examine mutation-specific cellular
differences. This comparison has been
achieved only in rare instances (Urbach
et al., 2004), although novel Zn finger
nuclease technology may change this
situation (Zou et al., 2009).
Monogenic diseases are an attractive
target because the gene and often its
product are known. This opportunity
might seem a recipe for predictable and
uninspired research; however, there are
many diseases where the impact of
a universally expressed mutant gene on
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pathies (Burke and Stewart, 2006), re-
mains unclear. In polygenic and complex
diseases, ignorance regarding gene loci
should not be an obstacle to an iPSC
approach—it may even facilitate their
identification. Syndromes, defined as dis-
eases with several distinct clinical fea-
tures, are of particular interest when
patterns of aberrant gene expression
and pathology cannot be superimposed,
because this discrepancy may point to
compensatory mechanisms of potential
therapeutic interest occurring in the unaf-
fected tissue.
Considerable insight into human dis-
ease pathology has been obtained via
animal models. Such models offer a com-
plementary approach to cellular models
and, as demonstrated in Figure 1, could
be pivotal to the validation of the iPSC/
ESC approach. However, for many mono-
genic diseases (e.g., Lesch-Nyhan, Du-
chenne muscular dystrophy, ataxia-telan-
giectasia), the animal models show no or
only an approximate resemblance to the
human disease, and more complex con-
ditions, particularly neurological diseases
that manifest themselves through cogni-
tive or behavioral deficits (like schizo-
phrenia and autism), are particularly diffi-
cult to model. In such instances, in vitro
models may offer a welcome alternative
to investigate the underlying molecular
mechanism on a cellular level.
A particularly challenging use of this
technology is when the disease is non-
cell autonomous. It is difficult enough to
make one cell type properly; to make
a second (or more) when the identity of
the participating cell types is unknown
seems untenable. However, in some situ-
ations, success with one cell type could
allow that cell population to be used to
pan for pathological mediators present
in bona fide human tissues. For example,
if iPSC-derived type 1 beta cells could be
generated, they could be exposed to
cellular and/or proteinaceous fractions
of blood taken from diabetic patients at
early and late stages of the disease. In
this way, the distinctive autoimmune
rejection of beta cells could be modeled
in vitro.
Many diseases exhibit a late onset in
humans. A legitimate concern regarding
the use of these pluripotent cellular mod-
els is whether the duration or conditions
of in vitro culture will be sufficient for the
disease pathology to emerge. Where
comparisons have been made, it seems
that early developmental milestones (i.e.,
beating cardiomyocytes) are achieved
with similar timelines in vitro and in utero;
i.e., development does not appear to be
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Figure 1. The Use of hiPSCs/hESCs in Disease Modeling and Drug Development
Pluripotent cells carrying a disease-linked mutation can be derived via iPSC from patient tissue samples,
by isolation of ESCs from preimplantation diagnosed embryos, or by genetic modification of existing
hESCs, hiPSCs, or somatic progenitors. Differentiation of these pluripotent cells can be used to study
the emergence of the disease phenotype in vitro or be used for drug screening or development.Cell Stem Cell 5,reflects some immutable developmental
clock or whether under the right condi-
tions specific tissues could be preco-
ciously generated remains unclear. It is
therefore too early to know whether this
issue poses a restrictive hurdle to a broad
use of the technology. Even if it were true,
the sweeping term ‘‘late onset’’ refers to
the appearance of clinical symptoms;
subclinical developments may occur a
lot earlier and may be captured by the
in vitro methodology. This concern also
ignores the fact that many cellular con-
trols exerted in situ are relieved on trans-
fer to cell culture. For example, fibroblasts
in vivo are generally in a quiescent state
(G0); in culture they are highly prolifera-
tive. Diseases that are exacerbated by
more frequent cell replication (e.g., those
involving faulty DNA repair like Fanconi
anemia or ataxia telangiectasia) can be
expected to develop more rapidly in vitro.
Furthermore, emergence of a disease
phenotype might be facilitated during
in vitro culture resulting from suboptimal
media formulations or by deliberately per-
turbing the system in a stress-inducing
way (e.g., serum starvation, O2 reduction,
heat shock, etc.).
Diseases such as Prader-Willi syn-
drome, Beckwith-Wiedemann, fragile X,
or Angelmann syndrome manifest them-
selves through epigenetic changes that
modify the normal parental imprinting. In
most cases, these epigenetic diseases
are caused by the deletion of the maternal
or paternal copy of an imprinted gene or
because of its deregulation resulting
from a defect in the machinery that gener-
ates the epigenetic mark. Parental im-
prints appear to be retained during re-
programming of mouse iPSCs (Wernig
et al., 2007). However, in both wild-type
mouse and human ESCs, these parental
imprints can be unstable during culture.
The epigenetic noise created in a cell
line can vary both in its severity and in
the identity of the imprinted gene(s)
affected at different times during culture.
This variation may compromise studies
into the mechanism of this type of epige-
netic disease. If these features are seen
also in hiPSCs, the nature of the epige-
netic misregulation and the underlying
mutation should be carefully considered
before initiating an iPSC-based approach
to model the disease.
Finally, for reasons that remain unclear,
hESC lines display distinctive andSeptember 4, 2009 ª2009 Elsevier Inc. 245
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Appropriate genetic modification of normal hESC (and probably iPSCs), particularly homologous
recombination, is very difficult. For monogenic diseases, there may be advantages in targeting genes in
somatic cells from unaffected donors prior to iPSC generation, although such modified lines will inherit no
clinical history.
PGD embryos (for hESC generation) are available for a limited number of diseases. In contrast, almost
unlimited disease coverage is available through patient-derived iPSCs. However, it remains unclear whether
iPSCs and hESCs have truly identical properties.
Animal model of the disease
available/not available
The unavailability or inadequacy of an animal disease model can be a prime motivator for undertaking an iPS-
based approach. Nevertheless, animal models are useful to test predictions arising from the in vitro approach.
Source of somatic cells
for iPSC reprogramming
Access to living patient material is preferred because often clinical records are better. For rare diseases, tissue
banks may provide the only source of cells along with limited patient information.
Monogenic or complex disease Monogenic diseases are simpler to model because knowledge of gene can inform experimental design. iPSCs
offer possibilities of novel approaches to unravel and identify interacting molecular components of complex
diseases.
Certain epigenetic diseases (e.g., those related to faulty parental imprinting) may be difficult to model if those
imprints are unstable in wild-type hESCs or hiPSCs.
Differentiation Related
Target cell type Certain lineages are difficult to generate in vitro and require genetic modification of hESCs. Constant
improvements of differentiation protocols will ease this limitation.
Afflicted tissues available
from patients
In vitro cell differentiation protocols are often suboptimal. It is important to compare in vitro manufactured cell
types with in vivo counterparts. Ideally, a host of functional (if available) and in vitro expression assays should




Many diseases show late clinical onset although pathological changes may occur much earlier. It is unclear
whether in vitro cell culture conditions will permit late-occurring pathologies to manifest themselves.
Consideration should be given to stressing cell in culture to accelerate pathogenic processes.
Cell- or non-cell-autonomous
disease
If non-cell autonomous, challenges of also crafting additional, often unknown, cell types are magnified.
Pathology easy/difficult
to measure
For some complex neurological diseases that cause behavioral changes, in vitro modeling might unravel some
of the molecular changes on a cellular level. Further (animal) modeling might be necessary to relate any
differences that are observed to disease pathology.
Function of gene product(s)
known/unknown
It is helpful to know function of a mutated gene; however, some genes produce several products and some
products have multiple functions, some or all of which are unknown.
Knowledge of gene product
function(s) explains/does not
explain clinical phenotype
Knowledge of the gene product function may deter choice of a particular disease if objective is to generate
new insight into disease mechanisms. However, known gene function may be irrelevant to the clinical
phenotype.
Methodology
Method of iPSC reprogramming Methods to generate iPSCs are rapidly evolving. Protocols that leave no genetic footprint are preferred so long
as such methods are sufficiently efficient to deal with somatic cell numbers available.
‘‘Points to Consider’’ is a format popular with the US Food and Drug Administration and other regulatory organizations that is used to appraise potential
sponsors of those technical and regulatory issues thought to be relevant for the preparation and approval of products/devices designed for clinical use
in humans.variable predispositions to differentiate
into specific lineages (Osafune et al.,
2008). This variation cannot be explained
by observable transcriptional differences
but may be attributable to subtle differ-
ences arising from the unique genetic
identity of each hESC line. In contrast,
multiple iPSC lines made from a single
patient should be genetically identical,
particularly if nonintegrative methods of
reprogramming are used. Nevertheless,246 Cell Stem Cell 5, September 4, 2009 ª2it remains possible that even these will
display functional differences as a result
of epigenetic drift between clones. This
hypothesis remains to be tested. In any
event, as a precautionary measure, sev-
eral clones should be studied from each
patient and although technically chal-
lenging, the specificity of a particular dis-
ease phenotype should be checked by
direct or indirect correction of the genetic
lesion.009 Elsevier Inc.hESC/hiPSC Models in Action
Eiges et al. (2007) were first to make and
derive novel early developmental informa-
tion from disease-specific pluripotent
stem cells. The authors investigated early
molecular events during differentiation of
hESCs made from PGD embryos har-
boring a fragile X mutation. This mutation
consists of a large (>200 repeat) triplet
(CGG) expansion in the 50UTR region of
the FMR1 gene, which results in the
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Foruminactivation of the gene and subsequent
severe mental retardation. By using
hESCFMR1, they showed that transcrip-
tional inactivation of the gene was trig-
gered by differentiation and preceded 50
hypermethylation of the locus.
Spinal muscular atrophy (SMA), an
autosomal-recessive disorder, is caused
by mutations in the SMN1 gene that lead
to reduced SMN protein levels. This loss
leads to selective decreased generation
of alpha motor neurons at a very early
age (around 6 months) with death fol-
lowing around 2 years of age. Ebert et al.
(2009) made iPSCs from the fibroblasts
of a SMA patient and his unaffected
mother. Less SMN protein was seen in
the iPSCSMA, and after motor neuron
differentiation of the two iPSC cultures,
smaller numbers of mutant motor neurons
accumulated on prolonged culture. SMN
levels in iPSCSMA and derived motor neu-
rons could be increased by addition of the
drugs valproic acid and tobramycin. It will
be interesting to see if these treatments
address the functional deficits in the
afflicted motor neurons.
Amyotrophic lateral sclerosis (ALS) is
a late-onset devastating disease that
leads to motor neuron degeneration.
One rare (<3% cases) form of this disease
is caused by a dominant mutation in the
superoxide dismutase gene 1 (SOD1).
This disease can be modeled in mice
where it has been shown to be non-cell
autonomous with strong evidence for
glial cell secretions triggering motor neu-
ron degeneration (Clement et al., 2003;
Di Giorgio et al., 2007). iPSCSOD have
been made from a symptomatic 82-year-
old patient and differentiated into motor
neurons and glia (Dimos et al., 2008), but
it is not clear yet whether these cells are
symptomatic in any way. Nevertheless, it
is encouraging to note that motor neurons
that can be differentiated from normal
hESCs are sensitive to the toxic effect of
mouse glial cells carrying an ALS-causing
mutation. This motor neuron loss has
been attributed to prostaglandin D2 sig-
naling and can be partially prevented by
addition of a prostaglandin D2 receptor
antagonist (Di Giorgio et al., 2007).
Future Perspectives
The prospect of observing the origin and
maturation of human genetic disease in
a dish is a tantalizing one although beset
by many challenges. We have presenteda list of questions that we feel partici-
pating scientists will want to consider.
Without doubt the optimization of cell
culture conditions that allow various cell
types to thrive, as well as issues of
disease onset are paramount to the
widespread adoption of this technology
for disease modeling. If human disease
pathologies (and in particular late-onset
pathologies) do not manifest themselves
under in vitro cell culture conditions, or if
a vast number of various cell types are
necessary to trigger a specific pathology,
this modeling approach will have limited
scope and thereby impact other sug-
gested uses of the technology. However,
if these hurdles are overcome, iPSC-
derived diseased lineages could expedite
the discovery of new compounds or the
testing of approved drugs in a new
context. In the decade since the first iso-
lation of human embryonic stem cells,
we have seen tremendous improvements
in culturing hESCs and directing their
differentiation toward specific lineages.
The provision of lineage-specific reporter
lines through the genetic manipulation of
hESCs (or better, iPSCs) in conjunction
with drug screens that will steer differenti-
ation toward a particular lineage will
accelerate these developments. Taking
into consideration the rapid and constant
improvements of iPSC generation, we are
cautiously optimistic that this technology
could improve our understanding of dis-
ease initiation and progression, as well
as open up new avenues for therapeutic
interventions.
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Note Added in Proof
While this paper was in press, Nature published
a study by Lee et al. (2009) wherein the researchers
generated patient-specific iPSCs to model
a peripheral neuropathy, familial dysautonomia
(FD). The authors tested the differentiation
capacity of the patient-derived iPSCs, investigated
the mechanism responsible for the disease by
studying the expression levels of the transcription
regulator IKBKAP, and used the lines to validate
candidate drugs based on their effects on in vitro
differentiation.
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